U.S., Jan. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07312188) titled 'A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma' on April 24, 2025.
Brief Summary: This is a single - arm, multi - cohort, open - label, multi - center Phase II clinical study. It aims to evaluate the efficacy and safety of F182112 combined with different administration regimens in patients with relapsed or refractory multiple myeloma.
Study Start Date: July 02, 2025
Study Type: INTERVENTIONAL
Condition:
Relapsed or Refractory Multiple Myeloma
Intervention:
DRUG: F182112+P
F182112 + P
DRUG: F182112+CD38
F182112+CD38
Recruitment Status: RECRUITING
Sponsor: Shandong New Time Pharm...